$4 M

ARTL Mkt cap, 16-Sept-2020
Artelo Biosciences Net income (Q3, 2020)-951.2 K
Artelo Biosciences EBIT (Q3, 2020)-951.4 K
Artelo Biosciences Cash, 31-May-20201.3 M

Artelo Biosciences Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

R&D expense

1.2m1.1m

General and administrative expense

509.0752.0107.5k508.3k952.3k

Operating expense total

509.0752.0107.5k1.8m2.0m

Depreciation and amortization

290.0510.0

EBIT

(15.2k)(29.7k)(232.8k)(2.3m)(3.2m)

Interest expense

Interest income

31.3k

Income tax expense

Net Income

(15.2k)(29.7k)(234.9k)(2.3m)(2.2m)

Artelo Biosciences Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

17.0k3.6k572.8k337.4k4.4m

Current Assets

17.0k3.6k574.3k396.4k4.4m

PP&E

563.0721.0

Total Assets

17.0k3.6k574.3k397.0k6.5m

Accounts Payable

1.7k12.9k28.6k529.3k348.9k

Current Liabilities

1.7k17.4k29.4k532.0k1.0m

Total Liabilities

1.7k17.4k

Common Stock

7.6k7.6k11.3k14.0k3.4k

Additional Paid-in Capital

38.8k38.8k827.9k2.5m10.3m

Retained Earnings

(30.5k)(60.2k)(295.1k)(2.6m)(4.8m)

Total Equity

15.3k(13.8k)544.8k(135.0k)5.5m

Financial Leverage

1.1 x-0.3 x1.1 x-2.9 x1.2 x

Artelo Biosciences Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(15.2k)(29.7k)(234.9k)(2.3m)(2.2m)

Depreciation and Amortization

290.0510.0

Accounts Receivable

(22.1k)13.3k

Accounts Payable

1.7k11.2k15.6k500.7k(180.4k)

Cash From Operating Activities

(13.5k)(18.5k)(216.8k)(1.6m)(2.8m)

Cash From Investing Activities

(845.0)(1.5m)

Cash From Financing Activities

15.8k5.1k785.3k1.4m8.4m

Net Change in Cash

2.3k(13.4k)569.2k(235.4k)4.1m

Interest Paid

1.5k

Income Taxes Paid

Artelo Biosciences Ratios

USDQ2, 2015

Financial Leverage

1.2 x